

Vaccine industry starts production of A (H1N1) influenza vaccine: Sartorius Stedim Biotech expands production

- Continued high order intake for consumables
- Additional shifts at several European sites
- Sartorius extends status as preferred supplier of the vaccine industry

Aubagne|Goettingen, June 22, 2009 – Sartorius Stedim Biotech (SSB), a leading international supplier to the pharma and biotech industries, has been increasing its production for consumables needed to manufacture vaccines. Effective immediately, additional shifts are being implemented at SSB's southern French sites in Aubagne and Lourdes. At these locations, SSB manufactures aseptic single-use bags and containers and further single-use products used to store and transport intermediate serum products. Moreover, the company has been receiving a significant number of additional orders for its disposable filters for sterile filtration of vaccines and their preliminary products, and is preparing to ensure fast delivery at short notice.

"Ever since the World Health Organization has identified a pandemic, it is certain that large quantities of vaccine against the swine flu have to be manufactured. Meanwhile, we have been receiving major orders from vaccine manufacturers on a nearly daily basis and are therefore now ramping up our production at selected sites," said Dr. Joachim Kreuzburg, CEO of Sartorius Stedim Biotech. "Our customers are now counting on being able to respond quickly and flexibly in meeting the demand for vaccines. This is precisely what we are enabling them to do based on our extensive range of single-use products. For this reason, we are much in demand as a partner and a supplier in this critical situation."

For the coming months as well, Sartorius Stedim Biotech is expecting to receive substantial additional demand for its consumables. Single-use products lend themselves perfectly for use in vaccine manufacture as they permit fast production startup and flexible control of the quantities manufactured. SSB products are used not only in established chicken-egg-based vaccine production methods, but also primarily in cell-culture-based procedures. In the meantime, several vaccine manufacturers have announced that they will be increasingly using cell-culture-based methods to produce their influenza vaccines as these methods result in considerable time savings and thus significantly improve their ability to respond in combating flu pandemics. For cell culture procedures, Sartorius Stedim Biotech offers the widest product portfolio available in the industry. Most recently, the company launched

Sartorius Stedim Biotech S.A.
Z.I. Les Paluds
Avenue de Jouques
B.P. 1051
13781 Aubagne - France

www.sartorius-stedim.com

Press:
Petra Kirchhoff
Phone +49 (0)551.308.1686

several types of new single-use bioreactors that have been specially designed for vaccine manufacturers as a target group, among other products. In this context, Sartorius Stedim Biotech was named a preferred supplier for yet another leading vaccine manufacturer.

On June 11, the World Health Organization (WHO) announced that it had raised its alert to the highest level and thus identified the first influenza pandemic in the 21st century. Since this time, the entire vaccine industry has been preparing to launch mass production of the swine influenza A (H1N1) vaccine. According to their own information, a few manufacturers have already begun full-scale production. Based on the most recent WHO information, some 44,300 infections with the swine flu virus have been registered; of this number, 180 patients have already died. Experts fear that the number of cases will strongly increase in the coming autumn and winter.

This press release contains statements about the future development of the Sartorius Stedim Biotech Group. The content of these statements cannot be guaranteed as they are based on assumptions and estimates that harbor certain risks and uncertainties.

A Profile of Sartorius Stedim Biotech

Sartorius Stedim Biotech is a leading provider of cutting-edge equipment and services for the development, quality assurance and production processes of the biopharmaceutical industry. Its integrated solutions covering fermentation, filtration, purification, fluid management and lab technologies are supporting the biopharmaceutical industry around the world to develop and produce drugs safely, timely and economically. For next-generation processes, Sartorius Stedim Biotech focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves.

Headquartered in Aubagne, France, Sartorius Stedim Biotech is listed on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and a global network of sales companies, Sartorius Stedim Biotech enjoys a worldwide presence. Its key manufacturing and R&D site is in Germany. The company employs over 2,300 people, and in 2008 generated sales revenue of 368.0 million euros.